The previous designations of full revision and focused update will be phased out. For additional information and poli- cies on guideline development, readers may consult the ACC/AHA guideline methodology manual4 and other Selection of Writing Committee Members The Joint Committee strives to ensure that the guide- line writing committee members have requisite content expertise and are representative of the broader cardio- vascular community. Experts are selected across a spec- trum of backgrounds, representing different geographic regions, sexes, races, ethnicities, intellectual perspectives or biases, and clinical practice settings. Organizations and professional societies with related interests and expertise are invited to participate as partners or collaborators. Relationships With Industry and Other Entities The ACC and AHA have rigorous policies and meth- ods to ensure that documents are developed without bias or improper influence. The complete policy on re- lationships with industry and other entities (RWI) can be found at https://www.acc.org/guidelines/about- guidelines-and-clinical-documents/relationships-with- industry-policy. Appendix 1 of the guideline lists writing committee members relevant RWI; for the purposes of CLINICAL STATEMENTS AND GUIDELINES full transparency, their comprehensive disclosure infor- mation is available online (https://www.ahajournals.org/ hensive disclosure information for the Joint Commit- tee is also available at https://www.acc.org/guidelines/ about-guidelines-and-clinical-documents/guidelines- and-documents-task-forces. Evidence Review and Evidence Review Committees In developing recommendations, the writing com- mittee uses evidence-based methodologies that are based on all available data.4 5 Literature searches fo- cus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, sys- tematic reviews, and expert opinion. Only key refer- ences are cited. An independent evidence review committee is commissioned when there are one or more questions deemed of utmost clinical importance that merit for- mal systematic review to determine which patients are most likely to benefit from a drug, device, or treatment strategy, and to what degree. 